12:00 AM
 | 
May 10, 1999
 |  BC Week In Review  |  Company News  |  Other News

Viragen infectious diseases news

VRGN is changing its focus from process manufacturing to clinical development now that its preclinical work on Omniferon multitype natural interferon alpha to treat hepatitis C is...

Read the full 112 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >